Targeting biologic markers in asthma - Is exhaled nitric oxide the bull's-eye?

New England Journal of Medicine

Volumn 352, Issue 21, 2005, Pages 2233-2235

  Deykin, Aaron ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; FLUTICASONE; NITRIC OXIDE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT;

ASTHMA; BIOASSAY; BRONCHUS HYPERREACTIVITY; CORTICOSTEROID THERAPY; EDITORIAL; EXPIRED AIR; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; BREATH ANALYSIS; NOTE; SENSITIVITY AND SPECIFICITY;

ADRENAL CORTEX HORMONES; ANDROSTADIENES; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; BRONCHODILATOR AGENTS; HUMANS; NITRIC OXIDE; SENSITIVITY AND SPECIFICITY;

EID: 19444384339     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058082     Document Type: Editorial

References (14)

1. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma - United States, 1980-1999. MMWR Surveill Summ 2002;51:1-13.
2. National Asthma Education and Prevention Program. Expert Panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, Md.: National Institutes of Health, 1997. (NIH publication no. 97-4051.)
3. National Heart, Lung, and Blood Institute. Global strategy for asthma management and prevention: global initiative for asthma. Bethesda, Md.: National Institutes of Health, 2002. (NIH publication no. 02-3659.)
4. British guideline on the management of asthma. Thorax 2003;58:Suppl 1:i1-i94.
5. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999;159:1043-51.
6. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
7. Smith AD, Cowan JO, Brassett KP, Herbison PG, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
8. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:253-6.
9. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003;326:1115.
10. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-12.
11. Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001;164:738-43.
12. Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005;115:720-7.
13. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994;149:538-51.
14. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28.